Rubicon Research
BSE: RUBICON · Pharmaceuticals
Snapshot
Unlock Rubicon Research's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Rubicon Research is a pharmaceutical company specialising in the development, manufacturing, and commercialisation of differentiated formulations. The firm maintains a strong focus on the United States generic and specialty drug markets.
Geography mix
- NaN%
Business Model
The company generates revenue primarily through the sale of differentiated pharmaceutical formulations within the US market.
- US Revenue Contribution (Q1 FY26):99.5%
Growth Outlook
Growth is driven by the company's established presence in the US specialty drug sector and its focus on differentiated formulation development.
Key Risks
- Geographic Concentration. The company's heavy reliance on the US market exposes it to significant regulatory and pricing risks within that specific jurisdiction.
- Regulatory Compliance. As a pharmaceutical manufacturer, the company faces stringent oversight from health authorities, where non-compliance could disrupt operations.
- Pricing Pressure. The US generic drug market is highly competitive, often leading to intense pricing pressure that can impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Rubicon Research and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Rubicon ResearchRUBICON | ₹29,245 Cr | 99.68 | 63.32 | — | 23.9% | 22.4% | 27.6% | — |
Wockhardt Ltd.WOCKPHARMA | ₹33,940 Cr | 82.88 | 40.10 | 18.4% | 25.1% | 8.9% | 10.4% | +41.5% |
Sai Life Sciences Ltd.SAILIFE | ₹33,605 Cr | 92.27 | 47.96 | — | 31.2% | 15.7% | 19.8% | +86.7% |
Neuland Laboratories Ltd.NEULANDLAB | ₹29,073 Cr | 58.41 | 36.78 | 78.3% | 33.5% | 29.3% | 35.4% | +55.1% |
Piramal Pharma Ltd.PPLPHARMA | ₹28,520 Cr | -90.39 | 26.16 | 0.8% | 13.6% | -3.9% | 1.4% | +7.7% |
Acutaas Chemicals LtdACUTAAS | ₹25,941 Cr | 67.17 | 45.18 | 40.9% | 39.0% | 26.1% | 34.3% | +122.4% |
As of Q1 FY27
Financials
Rubicon Research
BSE: RUBICON · Pharmaceuticals
Snapshot
Unlock Rubicon Research's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Rubicon Research is a pharmaceutical company specialising in the development, manufacturing, and commercialisation of differentiated formulations. The firm maintains a strong focus on the United States generic and specialty drug markets.
Geography mix
- NaN%
Business Model
The company generates revenue primarily through the sale of differentiated pharmaceutical formulations within the US market.
- US Revenue Contribution (Q1 FY26):99.5%
Growth Outlook
Growth is driven by the company's established presence in the US specialty drug sector and its focus on differentiated formulation development.
Key Risks
- Geographic Concentration. The company's heavy reliance on the US market exposes it to significant regulatory and pricing risks within that specific jurisdiction.
- Regulatory Compliance. As a pharmaceutical manufacturer, the company faces stringent oversight from health authorities, where non-compliance could disrupt operations.
- Pricing Pressure. The US generic drug market is highly competitive, often leading to intense pricing pressure that can impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Rubicon Research and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Q1 FY27